{"product_id":"clinical-dilemmas-in-non-alcoholic-fatty-liver-disease-isbn-9781118912034","title":"Clinical Dilemmas in Non-Alcoholic Fatty Liver Disease","description":"\u003cp\u003e\u003ci\u003eClinical Dilemmas in Non-Alcoholic\u003c\/i\u003e \u003ci\u003eFatty Liver Disease\u003c\/i\u003e offers hepatologists practical, up-to-date and expert guidance on the most topical dilemmas, difficulties and areas of controversy\/difficulty surrounding this ever-increasing area of liver disease they face in daily practice. \u003c\/p\u003e \u003cp\u003eRoger Williams and Simon Taylor-Robinson, two of Europe’s leading hepatologists, have recruited leading figures from across the world to assist them, resulting in a truly international approach.  Each chapter covers a specific area of difficulty, containing clear learning points and providing evidence-based expert guidance on the latest hot topics in clinical management such as:\u003c\/p\u003e \u003cul\u003e \u003cli\u003eIs NAFLD different in absence of Metabolic Syndrome?\u003c\/li\u003e \u003cli\u003eAre the pros outweighed by the cons of obtaining a liver biopsy?\u003c\/li\u003e \u003cli\u003eIs progression to cirrhosis more likely in children with NAFLD?\u003c\/li\u003e \u003cli\u003eWhat are the dangers as well as the true benefits of bariatric surgery?\u003c\/li\u003e \u003cli\u003eHow is it best to use antifibrotic agents in clinical practice?\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003e\u003ci\u003eClinical Dilemmas in Non-Alcoholic\u003c\/i\u003e \u003ci\u003eFatty Liver Disease\u003c\/i\u003e provides the answers to the questions and challenges that clinicians face every day in this area.  It is essential reading for hepatologists of all levels and researchers in hepatology, as well as all those involved in the care of patients with NAFLD, including gastroenterologists, pathologists and specialist hepatology nurses.\u003c\/p\u003e \u003cp\u003eList of Contributors vii\u003c\/p\u003e \u003cp\u003ePreface ix\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart I: Nature of the condition\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1 Non-alcoholic fatty liver disease: Hype or harm? 3\u003cbr\u003e \u003ci\u003eStephen H. Caldwell and Curtis K. Argo\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2 NAFLD: A worldwide problem 8\u003cbr\u003e \u003ci\u003eJoanna K. Dowman Geoffrey C. Farrell and Philip Newsome\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3 Is insulin resistance the principal cause of NAFLD? 15\u003cbr\u003e \u003ci\u003eIan F. Godsland Sanjeev Mehta Shareen Forbes Fabian Meienberg Michael Yee Simon D. Taylor‐Robinson and Desmond G. Johnston\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4 Paediatric NAFLD: A distinct disease with the propensity for progressive fibrosis 29\u003cbr\u003e \u003ci\u003eEmer Fitzpatrick and Anil Dhawan\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e5 Non‐alcoholic fatty liver disease (NAFLD) as cause of cryptogenic cirrhosis 36\u003cbr\u003e \u003ci\u003eJay H. Lefkowitch\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6 Is NAFLD different in absence of metabolic syndrome? 44\u003cbr\u003e \u003ci\u003eYusuf Yilmaz\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e7 Occurrence of noncirrhotic HCC in NAFLD 50\u003cbr\u003e \u003ci\u003eDawn M. Torres and Stephen A. Harrison\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e8 Fibrosis progression: Putative mechanisms and molecular pathways 61\u003cbr\u003e \u003ci\u003eWing‐Kin Syn and Anna Mae Diehl\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e9 When is it NAFLD and when is it ALD?: Can the histologic evaluation of a liver biopsy guide the clinical evaluation? 72\u003cbr\u003e \u003ci\u003eElizabeth M. Brunt and David E. Kleiner\u003c\/i\u003e\u003cb\u003e                                                                                                                \u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e10 Of men and microbes: Role of the intestinal microbiome in non-alcoholic fatty liver disease 82\u003cbr\u003e \u003ci\u003eMuhammad Bilal Siddiqui Mohammed Shadab Siddiqui and Arun J. Sanyal\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e11 Can genetic influence in non‐alcoholic fatty liver disease be ignored? 91\u003cbr\u003e \u003ci\u003eYang‐Lin Liu Christopher P. Day and Quentin M. Anstee\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e12 Is there a mechanistic link between hepatic steatosis and cardiac rather than liver events? 103\u003cbr\u003e \u003ci\u003eSoo Lim\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart III: Diagnosis and Scoring\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e13 How to best diagnose NAFLD\/NASH? 113\u003cbr\u003e \u003ci\u003eVlad Ratziu\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e14 The clinical utility of noninvasive blood tests and elastography 124\u003cbr\u003e \u003ci\u003eEmmanuel A. Tsochatzis and Massimo Pinzani\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e15 Are the guidelines—AASLD IASL EASL and BSG—of help in the management of patients with NAFLD? 131\u003cbr\u003e \u003ci\u003eCristina Margini and Jean‐François Dufour\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e16 Imaging methods for screening of hepatic steatosis 138\u003cbr\u003e \u003ci\u003eHero K. Hussain\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e17 Are the advantages of obtaining a liver biopsy outweighed by the disadvantages? 152\u003cbr\u003e \u003ci\u003eJeremy F. L. Cobbold and Simon D. Taylor‐Robinson\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e18 Screening for NAFLD in high‐risk populations 161\u003cbr\u003e \u003ci\u003eNader Lessan\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart IV: Value of treatment measures\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e19 Defining the role of metabolic physician 173\u003cbr\u003e \u003ci\u003eNicholas Finer\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e20 Should physicians be prescribing or patients self‐medicating with orlistat vitamin E vitamin D insulin sensitizers pentoxifylline or coffee? 182\u003cbr\u003e \u003ci\u003eHaripriya Maddur and Brent A. Neuschwander‐Tetri\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e21 Effects of treatment of NAFLD on the metabolic syndrome 189\u003cbr\u003e \u003ci\u003eHannele Yki‐Järvinen\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e22 What are the dangers as well as the true benefits of bariatric surgery? 196\u003cbr\u003e \u003ci\u003eAndrew Jenkinson\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e23 Liver transplantation: What can it offer? 203\u003cbr\u003e \u003ci\u003eRoger Williams\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart V: What does the future hold?\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e24 Molecular antagonists leptin or other hormones in supplementing environmental factors? 211\u003cbr\u003e \u003ci\u003eJonathan M. Hazlehurst and Jeremy W. Tomlinson\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e25 What is the role of antifibrotic therapies in the current and future management of NAFLD? 218\u003cbr\u003e \u003ci\u003eNatasha McDonald and Jonathan Fallowfield\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e26 Developmental programming of non‐alcoholic fatty liver disease 226\u003cbr\u003e \u003ci\u003eJiawei Li Paul Cordero and Jude A. Oben\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIndex 232\u003c\/p\u003e \u003cp\u003e\u003cb\u003eProfessor Roger Williams\u003c\/b\u003e CBE, runs the Institute of Hepatology at UCL, and is a twice former president of EASL. He has authored an incredible 2100 journal articles. Despite advancing years, he is still actively involved in clinical research -- 340 articles in the past ten years, and analysis by ISI shows him to be one of the most influential researchers in his field. The award of a CBE for services to medicine recognised his major contribution to the study of liver disorders over 25 years including leading the team who performed the first ever UK liver transplant. He also performed George Best's controversial liver transplant in 2002.\u003cbr\u003eProf Williams has had many awards, medals, honorary fellowships, and in 2006 was included by HRH The Queen in a celebration at Buckingham Palace to honour those who continue to contribute to public service beyond the age of 65yrs. He was made a Fellow of King's College London in 1992 and an Honorary Fellowship from UCL was conferred on him in 2008, in recognition of his distinguished career and outstanding service to UCL.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eProfessor Simon Taylor-Robinson\u003c\/b\u003e joined the Department of Medicine at Imperial College London in 1997, having previously been Senior Registrar in Gastroenterology and Hepatology at Hammersmith Hospital. He was awarded the Sir Francis Avery Jones Gold Medal by the British Society of Gastroenterology in 1999 and the Young Investigator Award of the Liver Section of the European Gastroenterology Association in 1997. He is currently Director of the Imperial Clinical Research Facility at St Mary's Hospital, London.\u003c\/p\u003e","brand":"Wiley-Blackwell","offers":[{"title":"Default Title","offer_id":47988932116709,"sku":"NP9781118912034","price":89.95,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9781118912034.jpg?v=1761782104","url":"https:\/\/k12savings.com\/products\/clinical-dilemmas-in-non-alcoholic-fatty-liver-disease-isbn-9781118912034","provider":"K12savings","version":"1.0","type":"link"}